W.R. Berkley Corp’s Aimmune Therapeutics AIMT Stock Holding History

W.R. Berkley Corp’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-39,789	Closed	-$1.37M	–	253
2020 Q3	$1.37M	Buy	+39,789	New	+$847K	0.2%	74

W.R. Berkley Corp's AIMT Position: Q4 2020 in Review

W.R. Berkley Corp sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 39,789 shares — an estimated $1.37M sold.

W.R. Berkley Corp first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $1.37M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

W.R. Berkley Corp reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
W.R. Berkley Corp sold 39,789 Aimmune Therapeutics shares in Q4 2020, an estimated $1.37M.
W.R. Berkley Corp first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
W.R. Berkley Corp's Aimmune Therapeutics position peaked at $1.37M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on W.R. Berkley Corp's 13F filing for Q4 2020, filed 16 Feb 2021.